OncoDNA supports cancer specialists by providing comprehensive characterization of a patient’s cancer.
Included in the AvH investment portfolio since 2016.
9.54 %
Beneficial interest AvH
Press releases - Growth capital
View AllRelated participations
Growth Capital
Confo Therapeutics
La mission de Confo est de développer de nouveaux modulateurs de GPCR pour les patients atteints de maladies graves, en mettant actuellement l'accent sur les maladies rares, la douleur périphérique et l'obésité.
Growth Capital
MRM Health
MRM Health, established in the Ghent biotech cluster, develops innovative human microbiome-based medicines.
Growth Capital
Vico Therapeutics
Vico Therapeutics is a Dutch biotech company developing novel Antisense-Oligonucleotide (ASO) therapies for rare diseases.